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http://www.molecular-cancer.com/content/14/1/5RESEARCH Open AccessmicroRNA-146a inhibits cancer metastasis by
downregulating VEGF through dual pathways in
hepatocellular carcinoma
Zheng Zhang†, Yang Zhang†, Xiu-Xuan Sun†, Xi Ma and Zhi-Nan Chen*Abstract: Growing evidence indicates that miR-146a is involved in carcinogenesis and tumor progression in several
human malignancies. However, the molecular details underlying miR-146a mediated regulation of its target genes
and its precise biological function in cancer, especially in hepatocellular carcinoma (HCC) remains unclear.
Methods: The expression levels of genes including miR-146a, APC, VEGF and HAb18G were examined in HCC cell
lines and patient specimens were compared with control levels using quantitative reverse transcription-PCR. The
functions of miR-146a and HAb18G in migration/invasion and liver metastasis formation were determined by transwell
and spleen injection assays, respectively. miR-146a related genes were determined by PCR array. The potential
regulatory targets of miR-146a were determined by bioinformatics and prediction tools, correlation with target
protein expression, and luciferase reporter assay. DNA methylation status of miR-146a promoter were performed
by PCR analysis of bisulfite-modified genomic DNA.
Results: We demonstrated that miR-146a expression was markedly downregulated in hepatoma cells and hepatoma
tissues compared to immortalized normal liver epithelial cells and normal hepatic tissues. DNA methylation of miR-146a
promoter correlated with its downexpression and with liver cancer metastasis. The restoration of miR-146a dramatically
suppressed HCC cell invasion and metastasis by repressing VEGF expression through upregulating APC, which inhibits
β-catenin accumulation in nucleus, and downregulating NF-κB p65 by targeting HAb18G. In human HCC, miR-146a
expression was negative correlated with increased HAb18G, VEGF, NF-κB p65 and beneficial prognosis.
Conclusion: This study identified a novel target of miR-146a and defined miR-146a as a crucial tumor suppressor in
human HCC that acts through multiple pathways and mechanisms to suppress HCC invasion or metastasis.
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Hepatocellular carcinoma (HCC) is one of the most
common malignancies and one of the leading causes of
cancer-related death worldwide [1,2]. Despite recent
advances in disease management and treatment, HCC
patients still have a very dismal long-term prognosis.
For advanced-stage HCC patients, the overall 5-year
survival rate is less than 5% [3]. The main challenges in
the treatment of HCC involve intrahepatic recurrence and
metastasis, which simultaneously predict poor outcome
for HCC patients. The identification of critical players* Correspondence: znchen@fmmu.edu.cn
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unless otherwise stated.that suppress these processes may lead to novel the-
rapeutic targets for improving the prognosis of these
patients. Various previous studies have identified some
key signaling transduction cascades that are implicated
in the progression, invasion, and metastasis of HCC,
such as the EGFR/PI3K pathway [4], the RhoGTPase/
Rho-effector pathway [5], the SAPK/JNK pathway [6],
and the Ras/MAPK pathways [7]. However, the under-
lying molecular mechanisms of HCC metastasis are far
from fully understood.
In the past decade, increasing attention has been paid
to the important biological and pathological roles of
microRNAs (miRNAs), a type of small conserved RNA
molecule of approximately 17–22 nucleotides in length
[8,9]. As post-transcriptional regulators of gene expres-
sion, these small non-coding RNAs complementarily bindThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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messenger RNAs (mRNAs), leading to either the deg-
radation of mRNAs or the inhibition of protein transla-
tion. miRNAs are involved in the regulation of most
cellular processes, including cell proliferation, migra-
tion, and apoptosis [10]. In recent years, numerous
studies have shown that aberrant expression of miR-
NAs is associated with the development and progres-
sion of various types of cancer, including HCC [10],
and some of these miRNAs function as tumor suppres-
sor genes or oncogenes [11,12]. MiR-146a is located on
human chromosome 5q34, which is a region that is
often deleted in human tumors [13], and has been
reported to be aberrantly expressed in several cancers. For
example, it is downregulated in breast [14], hormone-
refractory prostate cancer [15], and pancreatic cancer [16],
which indicates that miR-146a is a potential tumor
suppressor. MiR-146a has also been shown to inhibit
cancer cell metastasis by targeting IRAK-1 [17-19]. How-
ever, it remains unknown whether miR-146a is involved in
the regulation of HCC cell invasion and how this miRNA
mediates invasive inhibition.
In this study, we discovered that miR-146a is downregu-
lated in human HCC and likely suppresses hepatoma
cell invasion and metastasis by downregulating VEGF
expression through 2 signaling pathways. First, miR-
146a mediates the upregulation of APC, which leads to
the inhibition of the nuclear accumulation of β-catenin,
and second, this miRNA inhibits HAb18G/CD147
(HAb18G) expression, a direct target of miR-146a,
which consequently downregulates NF-κB p65. These
findings provide a framework for better understanding the
pathogenesis of HCC.
Materials and methods
Ethics statement and clinical specimens
Frozen and paraffin-embedded tissues from 53 HCC cases
were collected from XiJing Hospital of Fourth Military
Medical University, with patients provided prior consent
and approval of Fourth Military Medical University. The
study protocol was approved by the Ethics Committee
of the Fourth Military Medical University. The sample
enrollment criteria included those with HCC diagnosed by
two independent pathologists, detailed information on
clinical presentation and detailed follow-up data for at
least 3 years. All patients had been treated with a combin-
ation of surgery and platinum-based chemotherapy.
DNA isolation and bisulfite treatment and BS-PCR DNA
Sequencing
DNA was isolated using the QIAGEN DNAesasy Blood
and Tissue kit following the guidelines of the manufacturer.
DNA was modified sodium-bisulfite using the EpiTect
Bisulfite Kit (QIAGEN) according to the manufacturer’sinstructions. The CpG sites of miR-146a promoter region
were amplified by PCR containing bisulfite DNA template,
Hotstartaq, bisulfite specific primers following established
procedure. The detail information of primers is listed in
Additional file 1: Table S1. After PCR reaction. DNA frag-
ment were purified using the Cycle pure kit from Omega
bio-tek. The purified PCR fragments were cloned into
pGEM-T easy vector (Promega), and individual clones were
sequenced.
Cell culture and nuclear-cytoplasmic fractionation
The human HCC cell lines SMMC-7721, Huh-7, and
HepG2 and the human embryonic kidney cell line 293 T
(HEK 293 T) were purchased from Shanghai Institute
for Biological Sciences (Shanghai, China) and routinely
cultured in Dulbecco’s Modified Eagle Medium (DMEM)
(GIBCO BRL, Grand Island, NY) containing 10% fetal
bovine serum (Hyclone Laboratories, Logan, UT) at
37°C in a humidified atmosphere of 5% CO2. Nuclear-
cytoplasmic fractionation was performed using Nuclear
and Cytoplasmic Extraction Reagents (Beyotime, Wuhan,
China) according to the manufacturer’s protocol.
RNA extraction and quantitative real-time polymerase
chain reaction (qPCR)
Total RNA was isolated from cultured cell lines and
tissue samples using TRIzol Reagent (Invitrogen, CA),
according to the manufacturer’s instructions. For the
enrichment of normal liver cells, paraffin-embedded nor-
mal liver tissue samples from 11 hepatic hemangioma
patients were microdissected on HE-stained sections
using laser capture microdissection under a microscope
(Leica, LMD7000), according to the method described
previously [20]. Normal liver tissues were also collected,
and subsequent RNA isolation was performed using the
NucleoSpin® FFPE RNA kit (Macherey-Nagel) according
to the manufacturer’s protocol.
Reverse transcription (RT) reactions were performed
using the Prime-Script RT reagent kit (TaKaRa, Dalian,
China). The qPCR was performed using a SYBR Premix
Ex Taq™ II kit (Takara). For miR-146a detection, mature
miR-146a was reverse transcribed, with specific RT
primers that were designed as previously described [21],
and normalized by RUN6. The sequences of the PCR
and RT primers are listed in Additional file 1: Table S1.
Pathway-specific expression array
The human tumor metastasis RT2 profiler PCR array
PAHS-028Z (QIAGEN) was used to assess the effect of
miR-146a on the expression of 84 known metastasis-
related genes. Total RNA was isolated either from miR-
146a-transfected SMMC-7721 cells or from negative
control-transfected SMMC-7721 cells using the HP
Total RNA kit (Omega bio-tek). Total RNA was reverse
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(QIAGEN) with RT2 qPCR master mix containing SYBR
Green (QIAGEN), according to the supplier’s instruc-
tions. The real-time PCR reaction was performed with a
CFX384 real-time system (BIO RAD). Four reference
genes with the lowest standard deviations across repli-
cates were used in the analysis (B2M, GAPDH, HPRT1,
and RPLP0). Expression profiles were obtained from 3
independent experiments.
Cell apoptosis and cell cycle analysis
For cell apoptosis analysis, the cells were resuspended in
1× Binding Buffer, and 5 μl of Annexin FITC Conjugate
and 10 μl of Propidium Iodide Solution were separately
added to each cell suspension. The stained cells (1 × 105)
were then analyzed using a FACScalibur flow cytometer
(BD Biosciences).
For cell cycle analysis, the cells were harvested by
trypsinization, washed in ice-cold phosphate-buffered
(PBS), and then fixed in 70% ice-cold ethanol. The cells
were washed with PBS and resuspended in Staining
Solution (50 μg/mL propidium iodide, 1 mg/mL of RNase
A, and 0.1% Triton X-100 in PBS). Cell cycle profiles
of 2 × 105 cells were analyzed using a FACScalibur flow
cytometer (BD Biosciences).
Cell proliferation assay
SMMC-7721, HepG2, and Huh-7 cells were plated in
96-well plates at 3 × 103 cells per well after transfection
with miR-146a or anti-miR-146a for 48 h. Cells were
cultured for 24, 48, 72, and 96 h, and then the absorb-
ance at 450 and 630 nm was measured after incubation
with 10 μl of WST-1 (Roche Applied Science, Indianapolis,
IN, USA). Each assay was performed in triplicate.
Immunofluorescence analysis
Cells were fixed in 4% paraformaldehyde at room
temperature for 15 min, followed by permeabilization in
1 × PBS containing 0.2% Triton X-100 for 10 min at
room temperature. The cells were blocked in blocking
solution (1 × PBS containing 10% normal goat serum)
for at least 2 h. After being briefly washed, the cells were
incubated with a rabbit anti human β-catenin or NF-κB
p65 antibody at 4°C for overnight. After being washed, a
goat anti-rabbit IgG conjugated with Alexa Fluor 488
(Invitrogen) was incubated with the cells at room
temperature for 1 h. DAPI (Sigma) was used to stain the
DNA. The fluorescence images were acquired using a
laser scanning microscope (A1, Nikon, Japan).
Immunohistochemical staining
Fresh-frozen tissue samples were formalin-fixed, paraffin-
embedded, and then cut into 5-μm sections. Immunohis-
tochemical staining for the HAb18G [22], APC and VEGFwas performed, and the expression level was independ-
ently evaluated by 2 senior pathologists according to
the proportion and intensity of positive cells. A score
of 0 (no staining), 1 (any percentage with weak inten-
sity or <30% with intermediate intensity), 2 (>30% with
intermediate intensity or <50% with strong intensity)
or 3 (>50% with strong intensity) was assigned to each
sample.
Vector construction
The expression vectors for miR-146a (pcDNA3.1-miR-
146a) and HAb18G (pcDNA3.1-HAb18G) were con-
structed by cloning the miR-146a precursor sequences
amplified from the genomic DNA of SMMC 7721 cells
and the HAb18G open reading frame (ORF) sequence
(without 3′-UTR) amplified from the total RNA of
SMMC 7721 cells into the multiple cloning site of the
mammalian expression vector pcDNA3.1 (Invitrogen,
CA). In addition, we generated 2 luciferase reporter
vectors with a wide-type (pGL3-HAb18G wt) or
mutant (pGL3-HAb18G mut) 3′-UTR fragment of
HAb18G inserted downstream of the stop codon of the
firefly luciferase gene in the pGL3 vector (Promega).
The 3′-UTR fragment of HAb18G for both pGL3-
HAb18G wt and pGL3-HAb18G mut contained puta-
tive binding sites for miR-146a, whereas the mutant
3′-UTR of pGL3-HAb18G mut carried a mutated
sequence in the complementary site for the seed region
of miR-146a. The sequences of all primers used in
vector construction are provided in Additional file 1:
Table S1. All constructed vectors were confirmed by
direct sequencing.
Wound migration and invasion assay
Cells transfected with miR-Ctrl/miR-146a, or nonrelative
control moleculars (NC)/antagomiR-146a were plated in
24-well culture plates at a density of 105 or 2 × 105
(Huh-7, hepG2) cells per well, and incubated for 24 h or
48 h (Huh-7, hepG2) to reach confluence. Using a 200 μl
tip, a wound was made in the monolayer (at time 0). The
cells were then washed with PBS and incubated. The
distance between the two sides of the wound was mea-
sured with an Olympus CX71 microscope (Olympus).
The distance between the two sides of the wound after
20-72 h of migration was divided from the distance at
time 0 and represented on a graph.
The invasion abilities of cultured cells were measured
using an in vitro transwell assay with modified Boyden
chambers containing polycarbonate filters (Millipore,
MA), according to the manufacturer’s instructions. Cells
transfected with miR-146a/miR-Ctrl, or antagomiR-146a/
nonrelated control molecules (NC) were plated 24 h after
transfection in serum-free medium and allowed to invade
towards a 10% FBS medium for 24 h, or 48 h. Cells that
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that invaded the underside of the filter were fixed and
stained with crystal violet.
Generation of SMMC-7721-miR-146a stable cell lines
Pre-miR-146a were amplified by PCR using cDNA from
SMMC-7721 cells and cloned into pcDNA3.1 vector.
The pcDNA-miR-146a and the empty vector alone were
transfected into SMMC-7721 cells using lipofectamine
2000 (Invitrogen). At 48 h post-transfection the cells
were culture in complete medium with 400 μg/ml G418
for 4 weeks.
In vivo metastasis assay
An experimental metastasis model in athymic nude mice
was developed using the HCC cell line SMMC-7721,
which has relatively strong in vivo invasive and meta-
static properties, as previously described [23]. Briefly,
nude mice were anesthetized with pentobarbital and a
transverse incision was made in the left flank through
the skin and peritoneum. The spleen was carefully ex-
posed and 2 × 106 viable SMMC-7721 cells transfected
with pcDNA3.1 or pcDNA-pre-miR-146a were injected
under the spleen capsule via a 27-gauge needle. Six
weeks after the injection, the mice were sacrificed under
anesthesia and tumor metastasis was examined under a
stereo microscope.
Luciferase reporter assay
The 3′-UTRs of Ehmt2, mpzl1, rhoA, kif2c, and HAb18G
were amplified by PCR and cloned downstream of the
luciferase gene in the pGL3 reporter vector (Promega).
Cells (3 × 104) were seeded in triplicate in 24-well plates
and allowed to settle for 24 h. Then, approximately
100 ng of pGL3-HAb18-3′-UTR (wt or mut) and 1 ng
of pRL-TK Renilla plasmid (Promega) were transfected
into cells using Lipofectamine 2000 (Invitrogen) accord-
ing to the manufacturer’s recommendations. Luciferase
and Renilla signals were measured 48 h after trans-
fection using the Dual Luciferase Reporter Assay Kit
(Promega) according to the manufacturer’s protocol.
Three independent experiments were performed, and
the data are presented as the mean ± SD.
Western blotting
Western blotting analysis was performed according to
the standard protocol described previously [22].
The samples were subjected to SDS-PAGE and trans-
ferred onto a polyvinylidene fluoride membrane. The
primary antibodies used in this study were as follows:
anti-HAb18G (1:4,000 [24], prepared by our lab), rabbit-
anti-β-catenin (1:500, Santa Cruz), rabbit-anti-APC
(1:500, Boster), rabbit-anti-VEGF (1:400, Boster), rabbit-
anti-NF-κB p65 (1:400, Boster), and an anti-α-tubulinantibody as a loading control. The secondary antibodies
used were either goat anti-mouse or goat anti-rabbit IgG
(PIERCE), depending on the primary antibody used.Statistical analysis
Statistical significance was evaluated using the Student’s
t-test for paired comparisons. All values are expressed as
the mean ± SD. P values <0.05 (using a 2-tailed paired t-
test) were considered to indicate significantly significant
differences between 2 groups of data. Non-metastasis
time data were represented using Kaplan Meier curves
and differences were compared by means of the pairwise
log-rank test.Results
MiR-146a is frequently down-regulated in HCC and
associated with tumor invasion and metastasis
In attempt to explore that miR-146a expression levels
differ between tumor and non-tumor tissues, we exam-
ined the expression in 11 pairs of HCC tissues and
matched tumor adjacent tissues. As shown in Figure 1A,
the comparative analysis indicated that miR-146a was
differentially downregulated in all 11 examined tumor
tissues paired with adjacent non-tumor tissues from the
same patient. Consistent with our results, published
microarray data have also shown that miR-146a is down-
regulated in HCC tissues as compared to matched
non-cancer liver tissue (Figure 1B, n = 96, NCBI/GEO/
GSE22058). Then, we detected miR-146a expression in a
panel of cell lines (SMMC-7721, Huh-7, and HepG2)
and in a cohort of HCC patients (n = 53) and normal
liver samples (n = 11), and observed that miR-146a was
downregulated in all 3 HCC cell lines as compared to
normal liver cells that were microdissected from 7 nor-
mal liver samples (Figure 1C), similarly, miR-146a level
was downexpressed in HCC samples compared to those
in normal liver samples (Figure 1D). Altogether, these
results indicate that miR-146a is downregulated in HCC.
The human HCC cell line SMMC-7721, which has negli-
gible levels of endogenous miR-146a, was found suitable
for miR-146a overexpression studies. Because miR-146a
expression levels in the Huh-7 and HepG2 cell lines
were much higher than in SMMC-7721 cells, the miR-
146a inhibition studies were performed in these cell
lines. Furthermore, the relationship between the expres-
sion of miR-146a and the clinical characteristics of HCC
patients was analyzed, which showed that miR-146a
expression is unrelated with tumor size, however, the
level of miR-146a is remarkably lower in HCC patients
with metastasis (n = 26) than in those without (n = 17)
(Figure 1E and F). All together, these results suggesting
the important roles of miR146a in pathogenesis of HCC
and prognosis of HCC patients.
Figure 1 Downregulation of miR-146a in human HCC cell lines and tissues. A. miR-146a expression was examined in paired primary HCC tissues
(T) and their match adjacent non-tumor tissues (NT) of 11 individual patients. The miR-146a levels were normalized to RUN6 expression. B. miR-146a is
decreased in HCC tissues compared with in matched non-tumor liver tissues (n = 96; NCBI/GEO/GSE 22058). P value was calculated by Student’s test. C.
and D. Real-time RT-PCR analysis of miR-146a expression in human normal liver tissues and HCC cell lines (C)., including SMMC-7721, Huh-7 and HepG2,
and in 53 HCC cases (D). miR-146a levels were normalized to RUN6 expression. P value was calculated by Student’s test. E. Real-time RT-PCR analysis
of miR-146a expression in 28 big HCC tissue samples (≥ 5 cm) and in 15 small HCC tissue samples (< 5 cm) was determined by real-time RT-PCR
and normalized to the level of RUN6. P value was calculated by Student’s test. F. Real-time RT-PCR analysis of miR-146a expression in 26 HCC tissue
samples with metastasis and in 17 HCC tissue samples without metastasis was determined by real-time RT-PCR and normalized to the level of RUN6.
P value was calculated by Student’s test.
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As miR-146a was found to be the markedly down-
regulation in HCC. Firstly, we ruled out the possibility that
the gene copy number alternations in HCC genome using
real-time PCR (data not shown). Then, we performed a
demethylation experiment by treating HCC cancer cells
with 5-azaC and found an induction of miR-146a
(Figure 2A), which indicating DNA methylation is likely to
regulate miR146a expression in the liver. Furthermore, we
analyzed the methylation status of the miR-146a promoter
in HCC patient tumors (n = 22) and normal liver tissues
(n = 5). We found that 7 hypermethylated CpG sitesadjacent transcription start site in the promoter region
of miR-146a may in HCC compared with those in nor-
mal liver tissues though bisulfate sequencing (Figure 2B
and C), and one of seven site displayed trends of nega-
tive correlation between methylation and tumor metas-
tasis (p = 0.0548 for site 4, Figure 2D) .
MiR-146a inhibits HCC invasion and metastasis
Given the low level of miR-146a expression detected in
HCC tissues, we asked whether miR-146a may function
as a tumor suppressor and could affect cell migration or
invasion. To address this question, we transfected miR-
146a into SMMC-7721 and Huh-7 cells (Figure 3A).
Figure 2 The association between the expression and promoter methylation of miR-146a in human liver cancer tissues. A. Real-time
RT-PCR analysis of miR-146a expression in SMMC-7721 cells treated with 5-aZa-dC for 24 h. Error bars represent ± SD. A student t-test was
employed. (*, p < 0.05) (**, p < 0.01). B. Diagram of the locations of the CpG sites. Vertical bars represent CpG sites in the promoter of miR-146a.
C. Bisulfite genomic sequencing analyses of the miR-146a CpG site in normal liver tissues (n = 6) and HCC tissues (n = 22). The filled and open
boxes are represented methylated and unmethylated CpG, respe60ctively. Ten single clones are represented for each sample. Open boxes, 0%
methylation; light filled boxes, 0-50% methylation; black filled boxes, 50-100% methylation. NL, normal liver; HM, HCC with metastasis; HN, HCC
without metastasis. D. the association between methylation status of candidate position and HCC metastasis. Error bars represent ± SD.
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reduce the migration of SMMC-7721 cells, as detected
in scratch migration assays (Figure 3B and Additional
file 2: Figure S1A). Furthermore, the invasion rate of
cells was repressed by at least 60% in the presence of
miR-146a as compared to a negative control (Figure 3Cand Additional file 2: Figure S1D). Cell cycle and apop-
tosis analysis showed that this effect was not due to the
inhibition of the cell cycle or increased apoptosis
(Additional file 3: Figure S2A, S2B). WST-1 analysis
and PCNA expression results also showed that the
ectopic transfection of miR-146a did not affect cell
Figure 3 miR-146a inhibited cell invasion and metastasis in vitro and in vivo. A. Changes in miR-146a levels in SMMC-7721 and Huh-7
cells transfected with miR-146a or miRNA control (miR-Ctrl) for 48 h as measured by real-time RT-PCR. the datum represents the mean ± SD.
B. Quantification of wound healing assay of SMMC-7721 cells transfected with miR-146a or miRNA control (miR-Ctrl). the datum represents the
mean ± SD. *p < 0.05. C. In vitro invasion assay. Cells from the same transfection as in (B). were seeded into triplicate mitrigel coated invasion
chambers at 24 h post-transfection and allowed to invade toward serum for 24 h. The invading cell numbers on each filter were counted and
data were plotted. the datum represents the mean ± SD. The student’s t test was used to compare the difference between two groups. *p < 0.05.
D. Changes in miR-146a levels in Huh-7 and HepG2 cells transfected with antagomiR-146a or nonrelated control moleculars (NC) for 48 h as
measured by real-time RT-PCR. the datum represents the mean ± SD. E. Quantification (right) of wound healing assay of Huh-7 and HepG2 cells
transfected with antagomiR-146a or nonrelated control moleculars (NC). The student’s t test was used to compare the difference between two
groups. the datum represents the mean ± SD. *p < 0.05. F. In vitro invasion assay. Cells from the same transfection as in (E) were seeded into
triplicate mitrigel coated invasion chambers at 24 h post-transfection and allowed to invade toward serum for 48 h. The invading cell numbers on each
filter were counted and data were plotted. the datum represents the mean ± SD. The student’s t test was used to compare the difference between
two groups. *p < 0.05. G. Representative images of the liver, spleen and number of visible liver metastases in vector- or miR-146a treated mice. Nude
mice were injected under the spleen capsule with 2 × 106 vector or miR-146a stable transfected SMMC-7721 cells via a 27-gauge needle (n = 10 in each
group). H. Tumor nodule number were counted (n = 10 in each group). Data are mean + SD. * p < 0.05.
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lar results were found in Huh-7 cells (data not shown).
Furthermore, we took advantage of the fact that miR-146a
is expressed in Huh-7 and HepG2 cells and performed
antagomiR-mediated loss of functional experiments
(Figure 3D), and found that the migration of these cells
increased by 39% and 18% (Figure 3E, Additional file 2:
Figure S1B, and S1C), and the invasiveness of these
cells increased by 41% and 11%, respectively (Figure 3F,Additional file 2: Figure S1E). These results demon-
strate that miR-146a may function as a tumor suppressor
in vitro.
In order to test the antitumor effect of miR-146a
in vivo, we prepared a cell line SMMC-7721-146a (7721-
146a), which stable expression of miR-146a (Additional
file 2: Figure S1F). Then, we injected 7721-146a or wild-
type SMMC-7721 cells transfected with the blank vector
(named as vector) into the spleen of nude mice. Four
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scopically visible liver metastases was achieved in 7721-
146a group. An average of 33.3 ± 3 visible metastases
nodules were counted in mice implanted with vector
group, and an average of 25 ± 1.9 visible metastases per
mouse was observed in mice bearing 7721-146a cells
(P <0.001, Figure 3H). Examination of the lungs revealed
an average of 10 ± 1 visible lesions in mice injected with
vector group, whereas mice treated with 771-146a exhib-
ited an average of 6 ± 1 macroscopic lung metastases
(Additional file 2: Figure S1G). Altogether, these results
indicate that miR-146a can inhibit HCC cell migration
and invasion both in vitro and in vivo.
Overexpression of miR-146a upregulates APC and
downregulates VEGF in HCC cells
To understand the potential of miR-146a to inhibit metas-
tasis, we analyzed the expression patterns of 84 metastasis-
associated genes by RT2 profiler PCR array (QIAGEN)
in SMMC-7721 cells transfected with miRNA control
(miR-Ctrl) or miR-146a. MiR-146a overexpression sig-
nificantly increased adenomatous polyposis coli (APC)
levels, while VEGF was downregulated by miR-146a
(Additional file 4: Figure S3 and Figure 4A). To further
confirm these findings and to determine whether the
observed response was specific to miR-146a, we deter-
mined the expression levels of APC and VEGF in
HepG2 and Huh-7 cells transfected with antagomiR-
146a. We observed the downregulation of APC and the
induction of VEGF at 48 h after antagomiR-146a treat-
ment in Huh-7 cells, however, only a slight changes
were detected in HepG2 cells (Figure 4B). We think
about this results is due to cell specific characters.
Because APC, a tumor suppressor, has been reported
as a negative regulators of β-catenin localization [25,26],
and β-catenin can promote VEGF transcription [27]. In
addition, NF-κB also promotes VEGF expression [28,29].
Therefore, we hypothesized that miR-146a could inhibit
VEGFA expression through a dual signaling pathway
model via β-catenin and NF -κB. To test this hypothesis,
we first determined the expression level and cellular
location of β-catenin in SMMC-7721 cells transfected
with miR-146a or miR-Ctrl. Western blotting analysis
showed that the β-catenin level did not differ significantly
between SMMC-7721 cells transfected with miR-146a and
those transfected with the miR-Ctrl (Figure 4A). However,
fluorescence microscopy analyses showed that β-catenin
was found in both the nucleus (green) and cytoplasm of
miR-Ctrl cells, however, overexpression of miR-146a
resulted in the predominant localization of β-catenin in
the plasma membrane (Figure 4C). Consistent with our
fluorescence microscopy analyses, cellular fractionation
showed that miR-146a overexpression inhibited the
nuclear accumulation of β-catenin (Additional file 5:Figure S4A), indicating that miR-146a promotes cyto-
plasmic β-catenin accumulation through the APC path-
way. In contrast, the opposite patterns of expression were
detected in Huh-7 and HepG2 cells transfected with
antagomiR-146a (Figure 4D, and Additional file 5: Figure
S4B). In addition, we also found that the overexpression of
miR-146a in SMMC-7721 cells resulted in reduced NF–κB
expression levels (Figure 4A); immunofluorescence stain-
ing revealed that NF–κB protein was localized in cyto-
plasm (Figure 5G), however, the cells transfected with
miR-Ctrl showed NF–κB mainly localized in prenuclear
and nucleus region (Figure 5G). In contrast, miR-146a
downregulation relocated NF–κB from the cytoplasm to
the prenuclear and nucleus in Huh-7 cells transfected with
antagomiR-146a (Figure 5H). The ectopic expression
of either β-catenin or NF–κB in miR-146a-expressing
SMMC-7721 cells reversed the ability of miR-146a to
inhibit VEGFA expression and repress cells invasion
(Figure 4E, and Additional file 6: Figure S7B). These results
indicate that miR-146a represses VEGFA though the
β-catenin and NF–κB signaling pathways.
Having established the downregulation of VEGFA by
miR-146a in vitro, we next tested whether miR-146a
would suppress VEGFA expression and angiogenesis in
an animal model. We performed immunohistochemistry
to detect VEGFA expression in tumors from miR-Ctrl
and miR-146a-overexpressing mice and found that the con-
trol SMMC-7721 tumors showed higher levels of VEGFA
staining. In contrast, miR-146a-expressing SMMC-7721 tu-
mors showed only low levels of VEGFA staining (Figure 4F).
Furthermore, CD34, a specific marker of endothelial cells,
was used to detected angiogenesis. As shown in Figure 4F,
reduced tumor microvessel density was observed in the
miR-146a-expressing SMMC-7721 tumors compared to
the control tumors (P = 0.0258). In addition, plasma
VEGF levels were found to be decreased by 2.18 fold in
mice with miR-146a compared with those in mice with
miR-Ctrl (Additional file 7: Figure S5). Taken together,
miR-146a affects tumor angiogenesis.
HAb18G is a direct target of miR-146a in HCC cells
To understand the molecular mechanisms by which
miR-146a induces tumor invasion and metastasis, we
employed a tri-pronged approach to identify the poten-
tial downstream mRNA target(s) of miR-146a. First, we
analyzed the upregulated gene expression profile in the
Gene Expression Omnibus (GEO) database (GSE22058),
which contains both miRNA and mRNA microarray data
from 96 paired Hepatitis B Virus (HBV)-related HCC
and adjacent non-cancerous tissues. Second, we focused
on the mRNAs with increased expression in HCC tissues
with metastasis, which we obtained from another dataset
(GSE364). Third, we performed database searches in
miRNA target prediction programs (Targetscan). Ehmt2,
Figure 4 Overexpression of miR-146a enhance APC expression and inhibit VEGF expression. A. Western blotting analysis of APC, NF-κB
p65, VEGF and β-catenin (b-cat) in SMMC-7721 cells transfected with miR-146a or miRNA control (miR-Ctrl). B. Western blotting analysis of APC,
VEGF and β-catenin (b-cat) in Huh-7 and HepG2 cells transfected with antagomiR-146a or negative control (NC). C. β-catenin staining of SMMC-7721
cells transfected with miR-146a or miRNA control (miR-ctrl) for 48 h. Cell nuclei were stained with DAPI. Scale bars represent 50 μm. D. β-catenin
staining of Huh-7 and HepG2 cells transfected with antagomiR-146a or negative control (NC) for 48 h. Cell nuclei were stained with DAPI. Scale
bars represent 50 μm. E. Western blotting analysis of β-catenin and NF-κB p65 expression in SMMC-7721 cells transfected with pcDNA3-β-catenin or
pcDNA3- NF-κB p65, respectively. F. Representative images of H&E staining, and VEGF and CD34 staining by immunostaining in SMMC-7721 xenograft
tumors; quantitation of the number of microvessels in 10 representative hpf’s (right); the datum represents the mean ± SD from 6 independently
treated tumors (P = 0.0258). Scale bar represents 100 μm.
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analysis because they are metastasis-related genes that
are frequently overexpressed in HCC tissues and also
contain a 3′ UTR element that is partly complementary
to miR-146a.To determine whether these 5 candidate mRNA tran-
scripts are regulated by miR-146a through direct binding
to its 3′ UTR, the 3′-UTR target sites of the candidate
mRNAs (either wild-type and mutant) were inserted
downstream of the luciferase promoter in the reporter
Figure 5 HAb18G is a potential target of miR-146a. A. Multiple species sequence alignment of the HAb18G/CD147 3′UTR including the
putative miR-146a target site sequence (upper). The pGL3- HAb18G reporter gene has the full length of HAb18G 3’-UTR cloned into pGL3 vector.
The pGL3- HAb18G -MUT vector has the four miR-146a binding sites mutated and confirmed by sequencing. SMMC-7721 were transfected with
pGL3- HAb18G or pGL3-HAb18G -MUT, respectively, together with miR-146a mimics or mimic negative control. The four predicted binding sites
of miR-146a were shown in the HAb18G 3′-UTR region. B. The relative luciferase activities were shown from three independent experiments. Error
bars represent ± SD. C. Western blotting analysis of CD147 in SMMC-7721 cells transfected with miR-146a or control miRNA (miR-Ctrl) (left panel).
Huh-7 and HepG2 cells were transfected with antago miR-146a or negative control (NC) (middle and right panel). D. Western blotting analysis of
CD147 in SMMC-7721-miR-146a cells transfected with CD147 without 3′-UTR region (CD147 Re). E. In vitro invasion assay of SMMC-7721 cells
transfected with CD147 siRNA for 24 h. The invading cell numbers on each filter were counted and data were plotted in fold change by defining
the number from control cells a 100%. Error bars represent ± SD. F. Western blotting analysis of APC, NF-κB p65 and VEGF in SMMC-7721 cells
transfected with HAb18G siRNA or scramble control. G-H. NF-κB p65 staining of SMMC-7721 cells transfected with miR-146a, CD147 siRNA or
miR-Ctrl (G), or Huh-7 cells transfected with antagomiR-146a and NC (H). Cell nuclei were stained with DAPI. Scale bars represent 50 μm.
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http://www.molecular-cancer.com/content/14/1/5vector. For luciferase assays, the miR-146a mimic or
scrambled control was co-transfected with different
luciferase 3′ UTR constructs and pRL-tk into SMMC-
7721 cells (Figure 5A). As shown in Figure 5B and
Additional file 8: Figure S6A, luciferase levels were
reduced by more than 50% in the presence of miR-
146a with the wild-type HAb18G 3′-UTR. This effect
was not observed when the miR-146a binding sites
were mutated. Thus, HAb18G is a potential target of
miR-146a. Downregulated luciferase activity was also
observed with the wild-type KIF2C 3′-UTR (Additional
file 8: Figure S6A), suggesting that HAb18G is not the
only direct target of miR-146a.
The effect of miR-146a on the endogenous expression
of HAb18G was subsequently evaluated, and we ob-
served a clear reduction in endogenous HAb18G protein
in SMMC-7721 cells that overexpressed miR-146a. On
the contrary, reduced expression of miR-146a in HepG2
and Huh-7 cells led to the increased expression of
HAb18G protein (Figure 5C). Collectively, these results
demonstrate that miR-146a downregulates HAb18G
expression at the post-transcriptional level by directly
targeting the 3′-UTR of the gene; therefore, HAb18G is
a bona fide target of miR-146a. To determine whether
the miR-146a-mediated suppression of HCC invasion
was mediated by HAb18G, we established SMMC-7721-
miR-146a cells overexpressing HAb18G from expression
vector without 3′-UTR (Figure 5D). Deletion of 3′-UTR
of HAb18G had induced the invasiveness of miR-146a
overexpressing cells (Figure 5E) and increased expression
of VEGF and NF–Κb p65 (Additional file 6: Figure S7).
In contrast, knockdown of HAb18G by siRNA led to
decreased VEGF protein level, NF–κB p65 level (Figure 5G),
and cells invasiveness (Figure 5E). However, no appar-
ent change in APC expression (Figure 5F), nor de-
creased nuclear accumulation of β-catenin (Additional
file 9: Figure S8) were related with HAb18G protein level.
These data indicate that HAb18G downregulation is
necessary, but not sufficient, to mediate the miR-146a-
induced reduction in human HCC cell invasive potential.
Furthermore, HAb18G is a potential target of miR-146a, but
other functional miR-146a targets remain to be identified.
MiR-146a expression was associated with decreased
HAb18G, VEGF and NF-κB, and longer overall
non-metastatic status in human HCC
To extend our analysis to clinical cancers, we measured
the expression of miR-146a in a cohort of 53 HCC samples
(26 cases without metastasis, and 27 cases with metastasis)
and 11 normal liver tissues. MiR-146a and HAb18G
mRNA were measured using real-time PCR analysis in
formaldehyde-fixed, paraffin-embedded tissues from the
patients, and immunohistochemical staining for VEGF,
NF-κB p65 and HAb18G were performed from thesame patients. In comparison to normal liver tissues,
the tumor samples showed an amplification of HAb18G
mRNA and a significant downregulation of miR-146a
expression (P < 0.001, Figure 1D, Figure 6A). Forty-seven
tumors showed positive HAb18G staining and were classi-
fied as stage 1 (n = 11), stage 2 (n = 16), or stage 3 (n = 20)
tumors. In addition, 6 tumors and 11 normal liver tissues
were classified as stage 0 (Figure 6B). We also observed
no significant difference in HAb18G mRNA expression
between HAb18G-positive and HAb18G-negative HCC
tissues (Figure 6C), suggesting that there may be post-
transcriptional regulation of HAb18G expression at the
protein level. Furthermore, miR-146a expression was
inversely correlated with HAb18G, VEGF and NF-κB
p65 protein expression (p = 0.0001, 0.0019, and 0.0453
respectively) (Figure 6D). We also found that NF-κB
p65 mainly localized to perinuclear and nuclear region
in low miR-146a expressed HCC tissues (Figure 6D).
Remarkably, low miR-146a expression was significantly
correlated with shorter non metastasis survival compared
to those with high miR-146a expression (P < 0.001,
Figure 6E).
Discussion
Human miR-146a is embedded on chromosome 5q34,
which is a region that is often deleted in HCC [13], and
has been reported to be aberrantly expressed in several
cancers. Other reports have shown that miR-146a func-
tions as a tumor suppressive miRNA in several kinds of
tumors, including pancreatic cancer, and breast cancers
cancer [16,30].
Our observation suggests that miR-146a was signifi-
cantly downregulated in HCC cell lines as compared to
normal liver tissue, which was consistent with our find-
ing that miR-146a was expressed at lower levels in HCC
tissues compared to adjacent non-cancerous tissues
(Figure 1A). It may play a role in HCC tumoregenisis as
a potential tumor suppressor. MiR-146a is also down-
regulated in metastatic HCC in comparison with non-
metastatic HCC from patients (Figure 1F). These results
suggest that miR-146a expression is often inhibited at
earlier stages of cancer progression and that its expres-
sion level contributes to metastatic dissemination. Our
observation also suggests that miR-146a is partially
regulated by methylation. MiR-146a expression was
restored in HCC cell lines upon administration of DNA
methylation inhibitor 5-aza-2′-deoxycytidine (Figure 2A).
Furthermore, we analyzed the methylation level of CpG
sites in miR-146a promoter by bisulfite sequencing, our
results suggest that the hypermethylation of the miR-146a
promoter may be associated with down-expression of
miR-146a in HCC tissues. Unfortunately, we could not
reveal the apparent relationship involved in the methyla-
tion level and metastatic in HCC tissues in this study.
Figure 6 Correlation between miR-146a and HAb18G/CD147, VEGF, NF-κB p65 expression, and prognosis in HCC tissues. A. Relative
expression of HAb18G/CD147 in HCC tissue and in normal liver tissue by real-time RT-PCR. B. Staining score of HAb18G/CD147 in HCC tissue and
in normal liver tissue by immunohistochemical staining. C. Relative expression of HAb18G/CD147 in immunohistochemical staining positive and
negative HCC tissue by real-time RT-PCR. D. Representative images of immunohistochemical staining for HAb18G, VEGF and NF-κB p65 in low
and high miR-146a expression cases (left). Scale bar represents 100 mm. Bar charts show the association between miR-146a expression and HAb18G,
VEGF and NF-κB p65. The low and high miR-146a expression was stratified by using average of miR-146a expression as threshold. The y-axes represent
HAb18G, VEGF and NF-κB p65 expression, as measured by immunohistochemical staining. Error bars represent ± SD. *p < 0.05, ** < 0.01. E.
Kaplan-Meier metastasis-free survival curves in miR-146a low and high expression HCC cases. The low and high miR-146a expression was stratified by
using average of miR-146a expression as threshold.
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tion level at one of seven the CpG site may related to
metastatic (Figure 2D). Further studies using larger sample
size are needed to reveal the relationship between miR-
146a methylation and miR-146a expression, and HCCmetastasis. MiR-146a was shown to directly inhibit expres-
sion of UHRF1 [31], an epigenetic regulator and coordinate
tumor suppressor gene silencing via DNA methylation [32]
in several cancers. Our results conjecture that repression of
miR-146a may promote self-methylation by upregulation of
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the expression of UHRF1 mRNA by qRT-PCR and the
methylation level by bisulfite sequencing in SMMC-7721
cells transfected with miR-Ctrl or miR-146a. The miR-146a
treatment cells exhibited low expression of UHRF1 and
lower methylation levels at seven CpG sites within the
miR-146a promoter in comparison to the controls
(Additional file 8: Figure S6C and D). These results
hinted that there is a negative feedback loop in miR-146a
expression. The further mechanism and function of this
feedback regulation in HCC need to be further studied.
We testified the putative tumor suppressor function
of miR-146a in human HCC by in vitro and in vivo as-
says. Ectopic expression of miR-146a could inhibit the
invasion and metastasis of HCC cells (Figure 3B and C),
and this effect was not due to suppressed cell cycle or
increased apoptosis (Additional file 3: Figure S2). How-
ever, downregulated miR-146a was able to promote cell
migration and invasion ability in 2 HCC cell lines (Huh-7
and HepG2) (Figure 3E and F). In nude mice, HCC cancer
cells overexpressing miR-146a displayed significantly fewer
metastatic loci than control cancer cells (Figure 3G,H and
Additional file 2: Figure S1G). Collectively, our data indi-
cate that miR-146a functions as a tumor suppressor in
HCC. Our results imply that miR-146a may function as a
negative regulator or tumor suppressor for cell invasion
and metastasis in HCC.
The molecular mechanisms involved in miR-146a-
mediated repression of metastasis are not well understood.
In our study, we found that miR-146a inhibits HCC inva-
sion and metastasis partly through the upregulation of
APC and the downregulation of VEGF (Additional file 4:
Figure S3 and Figure 4A). Adenomatous polyposis coli
(APC), a tumor suppressor, interacts with β-catenin to
inhibit Wnt signaling, is involved in multiple cellular
functions and processes, including cell migration [33].
Intact APC exerts its anti-tumor effect through the
accelerated degradation of β-catenin or by regulating
β-catenin nuclear export and the inhibition of signal
transduction by the lymphoid enhancer factor–T cell
factor (LEF-TCF) family of transcription factors [34].
Here, we found that ectopic miR-146a expression in-
creased APC protein levels and caused β-catenin to
relocalize from the nucleus to the cytoplasm (Figure 4C,D,
Additional file 5: Figure S4A and B). These findings
indicate that miR-146a may inhibit the Wnt/β-catenin
pathway by repressing nuclear β-catenin accumulation,
which consequently leads to the partial downregulation
of VEGF. However, the molecular mechanism involved
in the upregulation of APC expression by miR-146a
requires further investigation.
To date, several targets of miR-146a have been identi-
fied, such as IRAK-1 [17,18]. EGFR [16], UHRF1 [31]. On
the basis of our bioinformatics analysis and sequentialexperiments, we demonstrated that HAb18G is an add-
itional miR-146a target in HCC cells. There are several
lines of evidence to support this conclusion. First, based
on our analysis using publicly available algorithms
(TargetScan and miRanda), we found that HAb18G
mRNA is a theoretical target gene of miR-146a, with
potential binding sites conserved in multiple species
(Additional file 8: Figure S6B). Importantly, our lucif-
erase reporter assay results confirmed that miR-146a
overexpression significantly downregulated luciferase
activity by directly targeting the 3′-UTR of HAb18G
mRNA. However, this effect was eliminated when the
nucleic acids in the HAb18G 3′-UTR targeted by miR-
146a were mutated. Second, HAb18G protein expression
was significantly decreased in miR-146a-overexpressing
SMMC-7721 cells as compared to the NC. Moreover, im-
paired miR-146a expression resulted in increased HAb18G
protein levels in HepG2 and Huh-7 cells. Third, to further
elucidate mechanisms underlying the tumor suppressive
effect of miR-146a, we overexpressed HAb18G, but without
its endogenous 3′-UTR in SMMC-7721-miR-146a cells
and found that the invasion was increased, which suggest
that the regulation of miR-146a on migration and invasion
in HCC cells is related to HAb18G inhibition. We
established the miR-146a-HAb18G axis by rescue ex-
periment and the reverse correlation between miR-146a
and HAb18G expression in HCC samples.
We observed decreased VEGF levels after HAb18G
siRNA transfection and also found that elevated levels of
HAb18G mRNA lacking the 3′-UTR were able to upregu-
late VEGF expression. Therefore, miR-146a could down-
regulate VEGF levels through the inhibition of HAb18G,
leading to the suppression of cancer cell invasion and me-
tastasis. However, the molecular mechanism involved in
the upregulation of APC expression by miR-146a requires
further investigation.
It has been reported that miR-146a can regulate NF-
κB p65 signaling by targeting IRAK-1 [17,18] or EGFR
[16]. Importantly, we also observed decreased NF-κB
p65 levels after reexpressing miR-146a or after HAb18G
siRNA transfection (Figures 4A and 5F). Altogether, our
data indicate that miR-146a can indirectly downregulate
NF-κB p65 signaling by suppressing multiple molecules,
resulting in the inhibition of cancer cell invasion and me-
tastasis. On the other hand, Ectopic expression of NF–κB
p65 or β-catenin in SMMC-7721-miR-146a cells reversed
the effect of miR-146a to inhibit VEGFA expression
(Figure 4E) and promote cell invasion (Additional file 6:
Figure S7B). We also noted that decreased NF-κB p65
expression by siRNA could attenuate the HAb18G-
induced SMMC-7721-miR-146a cells and repressed
cells invasion (Additional file 6: figure S7C, D). These
results indicate that miR-146a repress VEGFA though
β-catenin and NF–κB signal pathway.
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ulation in HCC cells led to the upregulation of VEGF
via 2 signaling pathways: 1) the repression of APC ex-
pression, leading to β-catenin accumulation in nucleus,
and 2) a direct reduction in HAb18G expression, which
consequently promoted the expression of NF-κB p65.
These findings will contribute to our understanding of the
molecular mechanism by which miR-146a influences
tumorigenesis and may aid in the development of novel
cancer therapy strategies.
Additional files
Additional file 1: Table S1. primers and duplex.
Additional file 2: Figure S1. miR-146a inhibited cell invasion and
metastasis in vitro and in vivo. A. Represent figures of wound healing
assay of SMMC-7721 cells transfected with miR-146a or miRNA control
(miR-Ctrl). B-C. Represent figures of wound healing assay of Huh-7 (B.) and
HepG2 (C.) cells transfected with antagomiR-146a or negative control (NC).
D. Represent figures of invasion assay of SMMC-7721 cells transfected with
miR-146a or miRNA control (miR-Ctrl). E-F. Represent figures of invasion
assay of Huh-7 (E.) and HepG2 (F.) cells transfected with antagomiR-146a or
negative control (NC). G. Number of visible lung metastases (n = 10 in each
group). Data are present as mean + SD. * p < 0.05.
Additional file 3: Figure S2. Effect of miR-146a overexpression on HCC
cell function. A. Flow cytometry analysis of the cell cycle in miR-Ctrl or
miR-146a-transfected SMMC-7721 cells. B. Cell death was monitored
using fluorescein isothiocyanate (FITC)-labeled AnnexinV and PI staining
with flow cytometry. The right lower quadrant of each plot contains early
apoptotic cells, whereas the right upper quadrant contains late apoptotic
cells. This experiment was repeated 3 independent times, and similar results
were obtained each time. C. Cell proliferation assay (miR-NC-transfected or
miR-146a-transfected SMMC-7721 cells). C. Western blotting analysis of
PCNA protein expression in miR-NC-transfected or miR-146a-transfected
SMMC-7721 cells. Data represent the mean ± SEM of 3 independent
experiments. D. Western blot analysis of PCNA in SMMC-7721 cell transfected
with miR-Ctrl or miR-146a.
Additional file 4: Figure S3. RT2 profiler PCR array data from human
HCC cells SMMC-7721 cells transfected with miR-146a or miRNA control,
displayed as a scatter plot. Genes differentially regulated by more than
2-fold are indicated.
Additional file 5: Figure S4. Overexpression of miR-146a promote
β-catenin localized in cytoplasm. A. Western blotting analysis of β-catenin
expression in the cytoplasm and nuclei of SMMC-7721 cells transfected with
miR-146a or miRNA control (miR-Ctrl). Nuclear protein Histone H3 was used
as a nuclear protein marker, and GAPDH was used as a cytoplasmic protein
marker. B. Western blotting analysis of β-catenin expression in the
cytoplasm and nuclei of Huh-7 and HepG2 cell lines transfected with
antagomiR-146a. Nuclear protein Histone H3 was used as a nuclear
protein marker, and GAPDH was used as a cytoplasmic protein marker.
Additional file 6: Figure S7. Relative expression of VEGFA and NF-κB
p65 and in vitro invasion assay. A. Relative expression of VEGF and NF-κB
in SMMC-7721-146a cells transfected with HAb18G Re. Error bars represent ±
SD. *, p <0.05. B. In vitro invasion assay. SMCC-7721 cells transfected
with pcDNA-VEGF or NF-κB p65 were seeded into triplicate mitrigel
coated invasion chambers at 24 h post-transfection and allowed to invade
toward serum for 24 h. The invading cell numbers on each filter were
counted and data were plotted. The datum represents the mean ± SD. The
student’s t test was used to compare the difference between two groups.
*p < 0.05. C. Relative expression of NF-κB p65 in SMMC-7721-146a-HAb18G
cells transfected with siRNA. Error bars represent ± SD. *, p <0.05. D. In vitro
invasion assay. SMCC-7721-146a-HAb18G cells transfected with NF-κB p65
siRNA were seeded into triplicate mitrigel coated invasion chambers at
24 h post-transfection and allowed to invade toward serum for 24 h. The
invading cell numbers on each filter were counted and data were plotted.The datum represents the mean ± SD. The student’s t test was used to
compare the difference between two groups. *p < 0.05.
Additional file 7: Figure S5. VEGF level released into the plasma of
untreated, vector and miR-146a treated mice were detected by ELISA.
The datum represents the mean ± SD.
Additional file 8: Figure S6. Luciferase assay and Bisulfite genomic
sequencing analysis. A. Luciferase activities of various reporter plasmids in
HEK-293 T cells co-transfected with miR-146a or miR-Ctrl. Each experiment
was performed in triplicate and the luciferase activity was shown as mean ±
SD. A student t-test was employed. * refers to p < 0.05. B. Multiple species
sequence alignment of the HAb18G/CD147 3′UTR including the putative
miR-146a target site sequence (upper). C. Relative expression of UHRF1 in
SMMC-7721 cells transfected with miR- Ctrl or miR-146a. Each experiment
was performed in triplicate and the relative expression was shown as
mean ± SD. A student t-test was employed. * refers to p < 0.05. D. Methylation
status in SMMC-7721 cells transfected with miR- Ctrl or miR-146a. The filled
and open boxes are represented methylated and unmethylated CpG,
respectively. Five single clones are represented for each sample. Open
boxes, 0% methylation; light filled boxes, 0-50% methylation; black
filled boxes, 50-100% methylation. E. Represent figures of methylation
status in SMMC-7721 cells transfected with miR- Ctrl or miR-146a. Red
boxes shows methylation sites in miR-146a promoter.
Additional file 9: Figure S8. Immunofluorescence staining of β-catenin
(green) in SMMC-7721 cells transfected with siHAb18G. No differences in
localization were observed. Right: Overlay of β-catenin (green) and nuclear
DAPI (blue) staining. Scale bars, 50 μm.
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